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Background: Rheumatoid arthritis (RA) is a multisystem, autoimmune disorder and confers one of the
strongest risks for cardiovascular disease (CVD) morbidity and mortality.
Objective: To assess myocardial function and vascular stiffness in RA patients with and without car-
diovascular risk factors (CVRFs) using cardiovascular magnetic resonance (CMR).
Methods: Twenty-three RA patients with no CVRFs (17 female, mean age 52 ± 13 years), 46 RA patients
with CVRFs (32 female, mean age 53 ± 12), 50 normal controls (32 female, mean age 50 ± 11 years), and
13 controls with CVRFs (7 female, mean age 55 ± 7 years), underwent CMR at 1.5 Tesla, including
evaluation of left ventricular (LV) ejection fraction, strain, and vascular elasticity (aortic distensibility
[AD] and pulse wave velocity [PWV]). Disease activity and duration were recorded for each patient.
Subjects with known symptomatic CVD were excluded.
Results: LV volumes, mass, and ejection fraction were similar in the four groups. RA patients with CVRFs
showed the greatest abnormality in mid short-axis circumferential systolic strain, peak diastolic strain
rate, and vascular indices. RA patients without CVRFs showed a similar degree of vascular dysfunction
and deformational abnormality as controls with CVRFs. AD and total PWV correlated with myocardial
strain and RA disease activity. On multivariate regression analysis, strain was related to age, RA disease
activity, AD, and PWV.
Conclusion: CMR demonstrates impaired myocardial deformation and vascular function in asymptomatic
RA patients, worse in those with CVRFs. Subclinical cardiovascular abnormalities are frequent and appear
to be incremental to those due to traditional CVRFs and likely contribute to the excess CVD in RA.
© 2018 Hellenic Society of Cardiology. Publishing services by Elsevier B.V. This is an open access article
under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).c distensibility; CMR, Cardio-
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Rheumatoid arthritis (RA) is an autoimmune disorder of un-
known cause, resulting in a chronic, relapsing, and disabling
arthritis that is characterized clinically by painful joints, radiolog-
ically by erosions, and pathologically by synovitis with ﬁbrosing
pannus and a palisade of inﬂammatory cells. Extra-articular man-
ifestations commonly occur in genetically predisposed individuals
with RA,1 and the heart and vasculature are frequently involved,s is an open access article under the CC BY-NC-ND license (http://creativecommons.
tic resonance characterization of myocardial and vascular function in
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signiﬁcant morbidity and mortality.2 Cardiovascular disease (CVD)
accounts for 50-80% of the premature mortality in RA,3 and a
8e15 year reduction in lifespan.4 In fact, the risk of CVD, in the form
of myocardial infarction, heart failure, and stroke, in RA is higher
than that in non-RA patients with traditional CVRFs, including
diabetes mellitus,5 typically occurring in young, female RA patients
with no known CVD or CVRFs.6
Aortic distensibility (AD) and pulse wave velocity (PWV), ac-
quired using various non-invasive techniques, have been demon-
strated to be abnormal in patients with RA.7,8 As a chronic
inﬂammatory disease, RA also involves the myocardium to cause
myocarditis and cardiomyopathy,9 resulting in increased risk of
congestive cardiac failure, with both systolic and diastolic
dysfunction.10,11 Our group has previously reported on focal and
diffuse myocardial ﬁbrosis and myocardial inﬂammation that were
related to impairments in peak systolic and diastolic circumferen-
tial strain in RA.12
Rational planning of health care policy and interventional
measures are required to tackle CVD in RA patients. However,
several gaps exist in our knowledge, making it difﬁcult to plan
interventional strategies and base recommendations. First, the
frequency of vascular and myocardial dysfunction in RA patients
without known CVD or CVRFs is unknown. Second, the degree to
which conventional CVRFs interact with chronic inﬂammation in
RA to result in a speciﬁc cardiovascular phenotype is unknown.
Therefore, the aims of this study were (1) to assess vascular and
myocardial function in RA patients without known CVD or symp-
toms; (2) to assess the consequence of the interaction of CVRFs and
chronic inﬂammation in RA patients without known CVD, using
cardiovascularmagnetic resonance (CMR); and (3) to correlate CMR
ﬁndings to disease activity and chronicity.
2. Methods
2.1. Study subjects
Subjects with RA and no known CVD (n ¼ 69) were recruited
from 4 rheumatology centers in the United Kingdom. Inclusion
criteria were age greater than 18 years but less than 65 years (to
avoid the inﬂuence of age-dependent vascular and myocardial
changes); diagnosis of RA established independently by the
respective clinical team based on the American College of Rheu-
matology (ACR) 1987 criteria13 (modiﬁed 2010)14; and stable on
disease-modifying anti-rheumatic drugs (DMARDs) for at least
12 weeks. Patients were excluded from enrolment if they were
unable to tolerate CMR; had contraindications to CMR; had non-
sinus rhythm on a 12-lead electrocardiogram (ECG); had signiﬁ-
cantly impaired renal function (estimated glomerular ﬁltration rate
<30 ml/min); had impaired liver function (alanine aminotrans-
ferase more than twice the upper limit of normal); pregnant fe-
male; participated in another research study involving an
investigational product in the last 12 weeks before enrolment; and/
or were unable to give informed consent. Further, patients with
symptomatic CVD were excluded either on the basis of the medical
history, abnormal ECG, or prior abnormal coronary angiography. All
patients fulﬁlling the inclusion criteria were invited to participate.
The study was approved by the Oxfordshire Research Ethics Com-
mittee (Ref. 10/H0606/32), and all subjects gave written informed
consent before enrolment. A control group (n ¼ 63) that comprised
healthy subjects matched for age, sex, ethnicity (self-deﬁned), and
CVRFs was studied contemporaneously. The control subjects were
healthy volunteers recruited from the community, without prior
cardiovascular disease, and who had voluntarily responded to an
advert to participate in the study.Please cite this article in press as: Ntusi NAB, et al., Cardiovascular magne
rheumatoid arthritis patients, Hellenic Journal of Cardiology (2018), http2.2. Deﬁnition of CVRFs
Hypertension was deﬁned as a blood pressure >140 mmHg
systolic and >90 mmHg diastolic. Smoking was considered signif-
icant as a CVRF. Obesity was deﬁned as body mass index (BMI)
>30 kg/m2. Diabetes was deﬁned as a random serum glucose of
>11.1 mmol/L, a fasting serum glucose >7.0 mmol/L, or a 2-hour
postload glucose >11.1 mmol/L during an oral glucose tolerance
test following ingestion of 75 g of glucose. Dyslipidemia was
deﬁned as an elevated total cholesterol (>5.2 mmol/L), LDL
cholesterol (>2.6 mmol/L), triglyceride level (>1.7 mmol/L), or
reduced HDL cholesterol level (<1.0 mmol/L).
2.3. CMR image acquisition and analysis
2.3.1. Left ventricular cardiac volumes, mass, and function
Ventricular volumes, mass, and function were assessed with
CMR using a 1.5-Tesla Avanto MR system (Siemens Healthcare,
Erlangen, Germany) with steady-state free precession (SSFP),
retrospectively gated imaging, as previously described.15 Late
gadolinium enhancement (LGE) images were acquired with a
standard T1-weighted phase-sensitive inversion recovery sequence
8e10 minutes after a 0.15 mmol/kg gadolinium contrast (Gado-
terate meglumineeGd-DOTA, Dotarem, Guerbet LLC, France).
2.3.2. Myocardial tagging
Tagged cines were acquired with an ECG-triggered segmented
k-space gradient echo sequence with spatial modulation of
magnetization (SPAMM).16 Three short axes (basal, mid-ventricular,
and apical) scans and a single long axis (horizontal) scan were
obtained (see Fig. 1AeD).
2.3.3. Aortic pulse wave velocity and distensibility
CMR-based aortic PWV was measured using ECG-gated, spoiled
gradient echo sequences with velocity-encoding gradient for phase
contrast applied to assess through-plane ﬂow in the ascending
aorta (AA) and the proximal descending aorta (PDA) at the level of
the main pulmonary artery and also in the distal descending aorta
(DDA) 12 cm vertically down, just below the diaphragm, perpen-
dicular to the vessel17 (see Fig. 1EeG).
2.4. RA disease activity
Disease activity was assessed using the DAS28-CRP, a disease
activity score, which incorporates a 28-tender joint and swollen
joint count, in addition to a measure of general health, together
with the serum C-reactive protein level.18 An absolute level of
disease activity can be selected as a clinically meaningful goal for
therapeutic intervention; with a value of 3.2 deﬁned as the
threshold for a low disease activity state and <2.6 as the threshold
for remission.
2.5. Statistical analysis
Normality of data was tested using the KolmogoroveSmirnov
test. Normally distributed data are presented as
mean ± standard deviation (SD) or, where highly skewed, as
median (interquartile range); discrete data are presented as
numbers (percentages). The chi-square test or the Fisher exact test
was utilized to compare discrete data, as appropriate. ANOVAwith
post hoc Bonferroni correction was used to explore whether there
were differences between the four groups, i.e., RA patients
without CVRFs, RA patients with CVRFs, controls without CVRFs,
and controls with CVRFs. The ManneWhitney U test was used to
compare not normally distributed data between the two groups oftic resonance characterization of myocardial and vascular function in
s://doi.org/10.1016/j.hjc.2018.01.008
Fig. 1. Representative examples of short-axis cine images with myocardial tags in end-diastole and end-systole with systolic strain and diastolic strain rates in a RA patient (AeD)
and representative levels of the aorta where aortic distensibility and PWV were assessed (EeG). Cine tagging in a mid short-axis slice in end-diastole (A) and end-systole (B) in a
patient with RA and graphs showing peak systolic circumferential strain rate (C) and peak diastolic strain rate (D) in the same patient. E. The ascending aorta (AA) and the proximal
descending aorta (PDA) at the level of the pulmonary artery (PA) and in the distal descending aorta (DDA) 12 centimeters vertically down, perpendicular to the vessel; F. High-
resolution through-plane ﬂow image acquired at the level of the MPA including the AA and PDA; and G. High-resolution through plane ﬂow at the level of the DDA.
N.A.B. Ntusi et al. / Hellenic Journal of Cardiology xxx (2018) 1e8 3RA patients. Bivariate correlations were assessed using the Pear-
son “R” and Spearman “RS” coefﬁcients, as appropriate. Linear
regression analysis of determinants of vascular stiffness and
myocardial function was performed. All statistical tests were two-
tailed, with p values of less than 0.05 considered statistically
signiﬁcant. Analysis was performed using SPSS version 24 (IBM,
Armonk, New York, USA).Please cite this article in press as: Ntusi NAB, et al., Cardiovascular magne
rheumatoid arthritis patients, Hellenic Journal of Cardiology (2018), http3. Results
3.1. Baseline characteristics of the study population
RA patients were matched with controls for age, sex, and co-
morbidities (Table 1). Common DMARDs in RA included metho-
trexate (~90%), chloroquine (~60%), and sulfasalazine (~25%). RAtic resonance characterization of myocardial and vascular function in
s://doi.org/10.1016/j.hjc.2018.01.008
Table 1














Demographic features and co-morbidity
Female sex 32 (64) 7 (54) 17 (74) 32 (70) 0.61
Age, years 50 ± 11 55 ± 7 52 ± 13 53 ± 12 0.39
Hypertension 0 (0) 4 (31) 0 (0) 12 (26) e
Diabetes 0 (0) 0 (0) 0 (0) 4 (9) e
Obesity 0 (0) 6 (46) 0 (0) 14 (30) e
BMI, kg/m2 23 ± 3 28 ± 4 24 ± 2 28 ± 5 <0.001
Medical therapy
Methotrexate e e 21 (91) 39 (85) e
Chloroquine e e 13 (57) 26 (57) e
Sulfasalazine e e 6 (26) 5 (11) e
Leﬂunomide e e 2 (9) 9 (20) e
Rituximab e e 1 (4) 2 (4) e
Prednisolone e e 1 (4) 7 (15) e
Duration of DMARDs,
years (median ± IQR)
e e 3 (2e6) 6 (4e9) e
Duration of NSAIDs,
years (median ± IQR)
e e 2 (1e3) 3 (2e6) e
Disease activity and chronicity
DAS28-CRP e e 3 ± 1 4 ± 2 e
ESR, mm/h
(median ± IQR)





e e 19 (5e17) 12
(6e16)
e
Duration of RA disease,
years (median ± IQR)
e e 7 (3e10) 10
(7e13)
e
Continuous data are mean ± SD unless otherwise indicated.
Categorical data are frequency (percent) unless otherwise indicated.
AID, autoimmune disease; BMI, bodymass index; CAD, coronary artery disease; CRP,
C-reactive protein; CVRFs, cardiovascular risk factors; DAS28-CRP, rheumatoid
arthritis disease activity index, incorporating a 28-joint count and serum CRP;
DMARD, disease-modifying anti-rheumatic drug; ESR, erythrocyte sedimentation
rate; NSAID, non-steroidal anti-inﬂammatory drug; RA, rheumatoid arthritis.
The p value for female sex is based on the chi-square test, whereas the p values for
age and BMI are based on ANOVA analysis.
N.A.B. Ntusi et al. / Hellenic Journal of Cardiology xxx (2018) 1e84patients with CVRFs had a longer median duration of RA (10
[7e13] vs. 7 [3e10] years, p < 0.001) and had been on DMARDs
for longer time (6 [4e9] vs. 3 [2e6] years, p < 0.001). Further-
more, RA patients with CVRFs had higher disease activity (4 ± 2





LVEDV, ml/m2 77 ± 13 79 ±
LVESV, ml/m2 22 ± 15 20 ±
LVEF, % 74 ± 4 74 ±
LV Mass, g/m2 53 ± 10 58 ±
LA size, mm 26 ± 5 29 ±
Mid SA circumferential strain rate 19.2 ± 1.0 18
Peak diastolic circumferential strain rate (s-1) 121 ± 12 109
LGE, % 26 (52) 11 (
AA distensibility (103 mmHg1) 3.5 ± 2.2 2.2 ±
PDA distensibility (103 mmHg1) 4.2 ± 1.7 3.1 ±
DDA distensibility (103 mmHg1) 6.0 ± 2.3 4.4 ±
Aortic Arch PWV (m/s) 4.4 ± 2.5 5.5 ±
DDA PWV (m/s) 4.4 ± 2.3 6.0 ±
Total aortic PWV (m/s) 4.6 ± 2.2 6.0 ±
Continuous data are mean ± SD unless otherwise indicated.
AA, ascending aorta; CVRFs, cardiovascular risk factors; DDA, distal descending aorta; LA,
left ventricular end-diastolic volume; LVEF, left ventricular ejection fraction; LVESV, left
velocity; SA, short axis; RA, rheumatoid arthritis.
The p values in this table come from separate ANOVAs for the different variables where
Please cite this article in press as: Ntusi NAB, et al., Cardiovascular magne
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These data are presented in Table 2. There were no differences in
LV volumes, mass, and ejection fraction between RA patients
without CVRFs, RA patients with CVRFs, normal controls, and
controls with CVRFs, respectively. However, despite the normal
global LV systolic function, there was signiﬁcant impairment in
regional LV systolic and diastolic function in RA patients as assessed
by deformation indices (Fig. 1AeD). Midventricular circumferential
strain was more markedly reduced in RA patients compared to
other groups (Fig. 2A). There was also evidence of impaired dia-
stolic function with peak diastolic circumferential strain rate being
most affected in RA patients (Fig. 2B).
3.3. Late gadolinium enhancement
As previously reported,12 we found increased late gadolinium
enhancement in RA patients compared to control subjects (Table 2).
LGE was typically patchy and mostly involved the basal to mid
inferolateral walls and was more frequent in RA patients with
CVRFs.
3.4. Vascular function
These data are presented in Table 2. RA patients with CVRFs
showed the greatest reduction in AD and greatest increase in PWV
at the three different aortic levels (AA, PDA, and DDA), indicating
increased arterial stiffness in RA patients, which is worsened by the
co-existence of CVRFs (Fig. 2CeF). RA patients without CVRFs had
more severe abnormalities in both AD and PWV compared to
controls with CVRFs.
3.5. Arterial stiffness, myocardial strain, and covariates
There were signiﬁcant correlations between vascular indices
and deformation indices (Fig. 3). In detail, total PWV and distal
descending AD correlated with peak systolic strain rate (R ¼ 0.42,
p < 0.001 and R¼0.46; p < 0.001, respectively) and peak diastolic
strain rate (R ¼ 0.48, p < 0.001 and R ¼ 0.38; p < 0.001, respec-
tively). Further, AD correlated with age (R ¼ 0.69; p < 0.001) and
disease activity. Furthermore, peak systolic strain rate (RS ¼ 0.31;







16 80 ± 20 75 ± 14 0.45
6 24 ± 9 21 ± 9 0.56
3 71 ± 6 73 ± 7 0.22
12 56 ± 10 54 ± 11 0.21
5 31 ± 6 32 ± 6 <0.001
.2 ± 1.2 17.4 ± 1.3 16.8 ± 1.1 <0.001
± 29 82 ± 21 82 ± 20 <0.001
85) 2 (9) 5 (11) 0.002
1.4 2.3 ± 1.8 2.0 ± 1.6 0.002
1.5 2.8 ± 1.5 2.6 ± 1.4 <0.001
1.6 4.2 ± 1.9 3.8 ± 2.1 <0.001
3.2 7.2 ± 4.4 7.7 ± 3.7 <0.001
3.3 6.3 ± 2.9 7.3 ± 3.7 <0.001
1.7 6.8 ± 2.7 8.2 ± 3.3 <0.001
left atrium; LGE, late gadolinium enhancement; LV, left ventricle/ventricular; LVEDV,
ventricular end-systolic volume; PDA; proximal descending aorta; PWV, pulse wave
the ANOVA assumptions were met.
tic resonance characterization of myocardial and vascular function in
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Fig. 2. Systolic strain rate and diastolic strain rate and measures of vascular stiffness in RA patients, RA patients with CVRFs, normal controls, and controls with CVRFs. A. Peak
systolic mid SA circumferential strain rate; B. Peak diastolic mid SA circumferential strain rate; C. Ascending aortic distensibility; D. Proximal descending aortic distensibility; E.
Distal descending aortic distensibility; and F. Total aortic pulse wave velocity. NS, not statistically signiﬁcant (the mean difference is signiﬁcant at the <0.05 level). P values obtained
after Bonferroni correction. Circle indicates mean value and the error bars indicate the 95% conﬁdence interval.
N.A.B. Ntusi et al. / Hellenic Journal of Cardiology xxx (2018) 1e8 5the distal descending AD (RS ¼ 0.29; p ¼ 0.02) correlated with
disease activity.
On multivariate regression analysis, controlling for hyperten-
sion, smoking, BMI >30 kg/m2, diabetes, and hyperlipidemia, peak
systolic strain rate (0.04 [0.01e0.06]; p ¼ 0.09) and peak diastolic
strain rate were associated with age (0.47 [0.87e0.18]; p ¼ 0.02;
Table 3). Further, peak diastolic strain rate was associated with RA
disease activity (3.90 [7.29e0.51]; p ¼ 0.03), AD (3.11
[0.81e6.73]; p¼ 0.01) and PWV (1.60 [2.82e0.38]; p¼ 0.01). AD
was also inversely related to increasing age (0.01 [0.02e0.00];
p ¼ 0.04).Please cite this article in press as: Ntusi NAB, et al., Cardiovascular magne
rheumatoid arthritis patients, Hellenic Journal of Cardiology (2018), http4. Discussion
In this study, we used CMR to assess myocardial and vascular
structure and function in RA patients with no known CVD symp-
toms. Our data show that, while there is no difference in overall LV
systolic function (ejection fraction), size, and mass between RA
patients and matched controls, regional function assessed by strain
imaging is impaired in RA. Similarly, vascular function, assessed by
AD and PWV, is abnormal in RA patients. Interestingly, de-
rangements in both myocardial deformation and vascular elasticity
are most severe in RA patients with CVRFs. RA patients with notic resonance characterization of myocardial and vascular function in
s://doi.org/10.1016/j.hjc.2018.01.008
Fig. 3. Functional correlates of vascular stiffness and myocardial function. Pearson bivariate correlation between pulse wave velocity and peak systolic strain rate (A) and peak
diastolic strain rate (B); and Pearson bivariate correlation between distal descending aortic distensibility and peak systolic strain rate (C) and peak diastolic strain rate (D).
N.A.B. Ntusi et al. / Hellenic Journal of Cardiology xxx (2018) 1e86CVRFs and controls with CVRFs both show an intermediate
phenotype for myocardial and vascular function. Finally, we show
that impaired vascular function in RA correlates with disease ac-
tivity and impaired myocardial strain. These data may have impli-
cations for the clinical care of patients with RA, showing there is
signiﬁcant cardiovascular involvement even in asymptomatic pa-
tients, which is worsened by presence of CVRFs. Moreover, these
data suggest that early identiﬁcation of cardiovascular involvement
in RA, with sensitive non-invasive imaging techniques like CMR,
may permit earlier intervention, thus potentially reducing the ef-
fect of CVD on RA morbidity and mortality.
There is conﬂicting evidence in the literature regarding LV
function and mass in patients with RA. In a previous report, we did
not ﬁnd any differences in LV function, chamber size, and mass
between RA patients and matched controls.12 Similarly, in this
study, we found no differences in LV volumes, function, and mass
between RA patients and matched controls, even in those RA pa-
tients with the most severe aberrations of myocardial and vascular
function. In contradistinction, Giles et al reported normal myocar-
dial structure and function in RA patients, but found slightly lower
myocardial mass in RA patients when compared to controls.19
Echocardiographic studies have reported inconsistent results with
some investigators ﬁnding reduced9 or normal systolic func-
tion,20,21 or even increased LV mass in RA subjects compared to
controls.22Please cite this article in press as: Ntusi NAB, et al., Cardiovascular magne
rheumatoid arthritis patients, Hellenic Journal of Cardiology (2018), httpAdding further support to the concept of subclinical involve-
ment in asymptomatic RA patients, a speckled tracking echocar-
diography study by Sitia and colleagues demonstrated that LV peak
systolic longitudinal and radial strains were abnormal in 22 RA
patients without known CVD when compared to matched con-
trols.21 The same study also showed evidence of diastolic
dysfunction in RA patients without cardiovascular dysfunction, as
assessed by tissue Doppler imaging. Similarly, peak systolic longi-
tudinal, circumferential, and radial strains were found to be
abnormal in 46 RA patients when compared to controls and that
chronic inhibition of interleukin-1 improved these deformational
abnormalities in RA.20 In a different study of 87 RA patients, global
longitudinal LV and RV strain was reported to be reduced in pa-
tients when compared with healthy controls, and strain abnor-
malities correlated with RA disease severity.23 In this study, we
found left atrial size to be increased in patients with RA and in those
with CVRFs. There is a tight interrelationship between left atrial
size and function and myocardial performance throughout the
cardiac cycle.24,25 We have also shown, using CMR, that peak sys-
tolic circumferential strain and peak diastolic strain rate are both
impaired in RA patients, and that the degree of impairment is worst
in those RA patients with CVRFs. We hypothesise that abnormal
strain reﬂects diastolic dysfunction from both focal and diffuse
myocardial ﬁbrosis, as we have previously demonstrated that strain
abnormalities in RA correlate with left atrial size, native T1 values,tic resonance characterization of myocardial and vascular function in
s://doi.org/10.1016/j.hjc.2018.01.008
Table 3
Linear regression analysis of determinants of vascular stiffness and myocardial function
Variable Univariate regression Multivariate regression*
В (95% CI) P value В (95% CI)
Peak systolic SA circumferential
strain rate (model 1)
Age 0.35 (0.01; 0.60) 0.008 0.04 (0.01; 0.06) 0.09
Duration of disease 0.26 (0.01; 0.61) 0.12
CRP 0.02 (0.01; 0.04) 0.06
DAS28-CRP 0.30 (0.10; 0.50) 0.003
LA size 0.51 (0.02; 1.03) 0.05
AA distensibility 0.34 (0.12; 0.08) 0.02
PDA distensibility 0.21 (0.42; 0.03) 0.05
DDA distensibility 0.15 (0.31; 0.01) 0.05
PWV 0.11 (0.03; 0.18) 0.005
Peak diastolic SA circumferential
strain rate (model 2)
Age 0.24 (0.66; 0.15) 0.02 0.47 (0.87; 0.18) 0.02
Duration of disease 0.01 (0.53; 0.51) 0.97
CRP 0.31 (0.55; 0.07) 0.006
DAS28-CRP 5.76 (8.70; 2.82) <0.001 3.90 (7.29; 0.51) 0.03
LA size 5.50 (13.69; 2.69) 0.18
AA distensibility 5.82 (0.97; 8.37) <0.001 3.11 (0.81; 6.73) 0.01
PDA distensibility 3.12 (0.20; 6.43) 0.06
DDA distensibility 2.89 (0.57; 5.21) 0.02 1.31 (0.02; 2.65) 0.05
PWV 1.83 (2.97; 0.69) 0.002 1.60 (2.82; 0.38) 0.01
Distensibility (model 3) Age 0.03 (0.04; 0.02) <0.001 0.01 (0.02; 0.00) 0.04
Duration of disease 0.01 (0.02; 0.02) 0.32
CRP 0.01 (0.96; 0.01) 0.17
DAS28-CRP 0.01 (0.14; 0.04) 0.31
LA size 0.16 (0.07; 0.01) 0.02
PWV (model 4) Age 0.15 (0.09; 0.21) <0.001
Duration of disease 0.17 (0.09; 0.25) <0.001
CRP 0.07 (0.05; 0.06) 0.81
DAS28-CRP 0.18 (0.36; 0.72) 0.51
LA size 1.40 (0.07; 2.72) 0.04
AA, ascending aorta; BMI, bodymass index; CRP, C-reactive protein; CI, conﬁdence interval; DAS28-CRP, rheumatoid arthritis disease activity index, incorporating a
28 joint count and serum CRP; DDA, distal descending aorta; LA, left atrium; PDA; proximal descending aorta; PWV, pulse wave velocity; SA, short axis.
* Stepwise regression analysis controlling for hypertension, smoking, BMI>30 kg/m2, diabetes, and hyperlipidemia.
N.A.B. Ntusi et al. / Hellenic Journal of Cardiology xxx (2018) 1e8 7and extracellular volume expansion.12 We found that abnormalities
in strain were associated with vascular stiffness parameters,
advancing age and RA disease activity. Our ﬁndings suggest that
CMR may potentially be a sensitive non-invasive tool for risk
stratiﬁcation in patients with RA and also important for early
identiﬁcation of patients with myocardial involvement, before
overt LV dysfunction and symptoms develop.
We show that vascular function is abnormal in RA patients
without symptomatic cardiovascular disease. In a Korean study of
262 RA patients, arterial stiffness was found to correlate with age
and systolic blood pressure, but not with disease-related factors.26
A study of 77 RA patients found evidence of increased arterial
stiffness, which correlated with age, mean arterial pressure, and C-
reactive protein (CRP).7 To the best of our knowledge, however, the
relationship between aortic stiffness and sophisticated parameters
of LV systolic and diastolic function has not been explored before in
an RA population. Indeed, we show that both AD and PWV correlate
with both systolic strain rate and diastolic strain rate. Furthermore,
we demonstrate that aortic stiffness was associatedwith RA disease
activity. These observations provide insights into a plausible
mechanistic association between disease activity and chronic/
episodic inﬂammation in RA with consequent vascular and
myocardial inﬂammation and ﬁbrosis. These interesting observa-
tions in RA cardiovascular pathobiology will need to be validated in
larger cohorts.
This study is limited by its cross-sectional design, which does
not permit inference of cause and effect. Second, we had relatively
small numbers in some of the groups; however, despite this limi-
tation, signiﬁcant differences are observed between the 4 groups
studied. Despite these limitations, we have achieved our aim of
using CMR to studymyocardial function and vascular stiffness in RA
patients with and without cardiovascular risk factors (CVRFs) and
have found interesting and novel results. CMR is potentially aPlease cite this article in press as: Ntusi NAB, et al., Cardiovascular magne
rheumatoid arthritis patients, Hellenic Journal of Cardiology (2018), httppowerful tool for study of the preclinical phenotype of cardiovas-
cular involvement in patients with RA.
5. Conclusions
We performed combined myocardial and vascular functional
assessment with CMR in RA patients and found evidence of
abnormal strain and vascular function, which is worse in older RA
patients with CVRFs. Additionally, vascular stiffness in RA correlates
with disease activity and impaired myocardial strain rate. In the
future, a comprehensive, non-invasive, multiparametric CMR ex-
amination may be important for early detection of CVD, risk-
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